Immucell ( (ICCC) ) has released its Q3 earnings. Here is a breakdown of the information Immucell presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ImmuCell Corporation, a company specializing in animal health products for dairy and beef cattle, has released its unaudited financial results for the third quarter of 2025. The company is known for its First Defense® product and is developing Re-Tain®, a treatment for mastitis in dairy cows.
In the latest earnings report, ImmuCell reported a decrease in product sales by 8% for the third quarter of 2025 compared to the same period in 2024. However, over the nine-month period ending September 30, 2025, the company saw a 7% increase in product sales, and a 16% increase over the twelve-month period. The company also achieved a net income of $1.8 million for the nine-month period, a significant improvement from a net loss of $2.7 million in the previous year.
Key financial metrics highlighted in the report include a recovery in gross margin to 42.6% for the nine-month period, up from 27.3% in 2024. The company also reported an adjusted EBITDA of $4.4 million for the nine-month period, a substantial increase from $35,000 in the same period last year. Despite a net loss of $140,000 in the third quarter, this was an improvement from a loss of $702,000 in the previous year.
Looking ahead, ImmuCell’s management remains optimistic about the company’s future. With sufficient inventory and a clean slate, the company is poised for product adoption and revenue growth. The ongoing development and market feedback collection for Re-Tain® also indicate potential future advancements in their product offerings.